
New treatments and clinical insights will be shared at this year's American College of Allergy, Asthma and Immunology Annual Scientific Meeting.

New treatments and clinical insights will be shared at this year's American College of Allergy, Asthma and Immunology Annual Scientific Meeting.

New technologies such as the 1726-nm laser and pneumatic assisted broad band light are emerging treatments in acne.

Study results were presented at the 2023 American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.

From reducing age spots to nurturing the lip microbiome and supporting sensitive skin, 3 studies presented at the 2023 Integrative Dermatology Symposium highlighted the transformative potential of botanicals in skincare.

If you weren’t able to attend the 2023 Society of Dermatology Physicians Fall Conference or want to review our latest coverage and interviews, our full recap has you covered.

Click here to answer today's poll.

Catch up on coverage from the fourth and final day of the 2023 SDPA Fall Dermatology Conference.

Allison Arthur, MD, discussed the importance of tailoring a treatment plan for adult women with acne vulgaris that best suits their lifestyle and current needs.

Mark Lebwohl, MD, spoke with Dermatology Times about his talk on IL-17 inhibitors.

Ted Rosen, MD, presented a session comprehensively discussing common dermatoses characterized by itch and pruritus.

The study was presented in a poster at the 2023 SDPA Fall Conference in Nashville, TN.

Catch up on coverage from the third day of the 2023 SDPA Fall Dermatology Conference.

Investigators said that additional, larger studies are needed to assess the safety of live attenuated vaccine administration for pediatric AD patients being treated with dupilumab.

Ami Greene, MD, discusses her beginner and intermediate SDPA fall conference sessions on dermoscopy.

Rebecca Vasquez, MD, presented a session on common, overlapping, and complex pigmented dermatoses.

Olushola Akinshemoyin Vaughn, MD, shared clinical pearls from her work in a vulvar dermatology clinic at the 2023 SDPA fall conference.

Once daily application of tapinarof cream 1% rapidly improved itch in adult patients with varying plaque psoriasis diseases severity, according to a poster presented at SDPA’s fall conference.

Lisa Swanson, MD, PhD, delves into clinical pearls from her SDPA fall conference sessions on infantile hemangiomas and challenging cases in pediatric dermatology.

Catch up on coverage from the second day of the 2023 SDPA Fall Dermatology Conference.

A poster presented at SDPA’s fall conference revealed key insights into the importance of close monitoring and preventative measures in patients with cSCC.

Douglas DiRuggiero, DMSc, PA-C, presented a comprehensive session at the SDPA fall conference on treatment selection for patients with psoriasis.

Tazarotene was significantly less irritating to the skin than trifarotene and numerically less irritating than adapalene, according to a poster presented at SDPA Fall 2023.

Joe Cari, MPAS, PA-C, spoke to SDPA Fall Conference attendees about the importance of maximizing the patient journey from arrival to check out and beyond.

More than 80% of patients did not experience an increase in number of draining tunnels associated with HS by week 52.

Robyn Siperstein, MD, FAAD, reviews highlights and takeaways from her SDPA Fall 2023 sessions discussing considerations in cosmetic dermatology, thought-changing research in aesthetics, and more.

Catch up on coverage from the first day of the 2023 SDPA Fall Dermatology Conference.

Orit Markowitz, MD, discusses pearls her SDPA fall conference sessions, "Melanoma Diagnosis, Outcomes and Survival," and "Advanced Conditions."

A post hoc analysis evaluated the safety, efficacy, and tolerability of IDP-126 gel in Black patients with moderate to severe acne, of which there are limited data and literature describing its outcomes in this patient population.

Renata Block, MMS, PA-C, delves into the important and ever-evolving role of physician assistants in dermatology.

The most common conditions or concerns patients reported having that may influence their selection of a JAK inhibitor included an increased risk of MACE and an age above 65 years.